TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7913970

Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 1 to 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 1-22 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 3-13 months
Number of subjects: 0
Study: 3061974

Group type: EXPERIMENTAL
Intervention: Glucagon (0.25-2 mg, administered intravenously or intramuscularly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous glucagon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29949232

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin (2 capsules, 5 mg each) once a day for 12 weeks
Number of subjects: 54
Study: 27912901

Group type: EXPERIMENTAL
Intervention: Follitropin delta
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Follitropin alfa
Number of subjects: 1329
Study: 25842795

Group type: EXPERIMENTAL
Intervention: Non-return catheter valve
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard urine bag
Number of subjects: 96
Study: 24005956

Group type: EXPERIMENTAL
Intervention: Simeprevir 50 mg QD with PegIFNα‐2a/RBV for 24 weeks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Simeprevir 100 mg QD with PegIFNα‐2a/RBV for 24 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: PegIFNα‐2a/RBV for 48 weeks (PR48 group)
Number of subjects: 92
Study: 21761708

Group type: EXPERIMENTAL
Intervention: Combination therapy of correction of deviated nasal septum and plasma radiofrequency ablation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Combination therapy of deviated nasal septum and partial inferior turbinectomy
Number of subjects: 116
Study: 19476470

Group type: EXPERIMENTAL
Intervention: Repaglinide/metformin FDC tablet BID
Number of subjects: 561

Group type: COMPARATOR
Intervention: Rosiglitazone/metformin FDC tablet BID
Number of subjects: 561
Study: 17326356

Group type: EXPERIMENTAL
Intervention: Toric iris-fixated phakic intraocular lens implantation
Number of subjects: 40
Study: 15179410

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg subcutaneously, administered twice daily on days 1 to 7)
Number of subjects: 12
Study: 11486699

Group type: EXPERIMENTAL
Intervention: pegylated-liposomal doxorubicin (PLD)
Number of subjects: 258

Group type: COMPARATOR
Intervention: doxorubicin, bleomycin, and vincristine (ABV)
Number of subjects: 258
Study: 9931845

Group type: EXPERIMENTAL
Intervention: Endoluminal procedure
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 98
Study: 7657854

Group type: EXPERIMENTAL
Intervention: 80-mg orlistat three times a day for 4 1/3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2713970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold environment (‐8 degrees C)
Number of subjects: 24
Study: 797075

Group type: EXPERIMENTAL
Intervention: Twice weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Once weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study: 31610995

Group type: EXPERIMENTAL
Intervention: E-mail alert sent to physician
Number of subjects: 3595

Group type: COMPARATOR
Intervention: Usual clinical care (control group)
Number of subjects: 3595
Study: 31386686

Group type: EXPERIMENTAL
Intervention: Asymptomatic individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptomatic individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children aged 0-5
Number of subjects: 0
Study: 28745783

Group type: EXPERIMENTAL
Intervention: Routine intravenous catheter fixation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Modified intravenous catheter fixation
Number of subjects: 110
Study: 26291952

Group type: EXPERIMENTAL
Intervention: Separated active electrode/camera cords
Number of subjects: 84

Group type: COMPARATOR
Intervention: Parallel oriented active electrode/camera cords
Number of subjects: 84
Study: 23958390

Group type: EXPERIMENTAL
Intervention: Vildagliptin plus metformin
Number of subjects: 3312

Group type: COMPARATOR
Intervention: Up-titration of metformin monotherapy
Number of subjects: 3312
Study: 21111399

Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 1159
Study: 19172219

Group type: EXPERIMENTAL
Intervention: Menatetrenone (45 mg daily for 6 months)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Calcium aspartate (133.8 mg of elemental calcium daily)
Number of subjects: 109
Study: 17234537

Group type: EXPERIMENTAL
Intervention: 16 mg of lycopene (Group A, n = 21)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 16 mg of lycopene along with biweekly intralesional steroid injections (Group B, n = 19)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (Group C, n = 18)
Number of subjects: 58
Study: 15189396

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11562416

Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: CsA + steroids (dual therapy)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: CsA + steroids + azathioprine (triple therapy)
Number of subjects: 354

Group type: COMPARATOR
Intervention: CsA monotherapy with steroids added
Number of subjects: 354
Study: 9565278

Group type: EXPERIMENTAL
Intervention: Dentine bonding agent (DBA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control tooth treated with DBA applied to coronal enamel
Number of subjects: 16
Study: 9202801

Group type: EXPERIMENTAL
Intervention: Pediatric Fat Emulsion 4501
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intralipid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 1792323

Group type: EXPERIMENTAL
Intervention: Boost dose in breast conserving therapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment planning techniques
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Use of wedge filters
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Collimator rotation and/or table wedge
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dose specification
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lung density corrections
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Planning system issues
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dose recalculation
Number of subjects: 16
Study: 7194655

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 422

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 422
Study: 31934996

Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 94

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study: 27988390

Group type: EXPERIMENTAL
Intervention: Mechanical therapy with adjunctive metronidazole
Number of subjects: 161

Group type: COMPARATOR
Intervention: Mechanical therapy without adjunctive metronidazole
Number of subjects: 161
Study: 26013203

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation (AA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Antidepressant switching (SW)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Aripiprazole augmentation (AA) and Antidepressant switching (SW)
Number of subjects: 101
Study: 24725616

Group type: EXPERIMENTAL
Intervention: Insulin lispro low mixture (LM25) twice daily
Number of subjects: 476

Group type: COMPARATOR
Intervention: Basal-prandial regimen of insulin glargine once daily and insulin lispro once daily (IGL)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 476
Study: 22032650

Group type: EXPERIMENTAL
Intervention: Photoactivated tissue bonding (PTB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 31
Study: 20927140

Group type: EXPERIMENTAL
Intervention: Minimally invasive posterior approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional posterior approach
Number of subjects: 50
Study: 18360287

Group type: EXPERIMENTAL
Intervention: Intermittent HAART (arm B)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Continuous HAART (arm A)
Number of subjects: 37
Study: 15761427

Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser at minimum purpura dose (MPD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 595-nm pulsed dye laser (PDL)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser at fluences greater than MPD
Number of subjects: 17
Study: 12211668

Group type: EXPERIMENTAL
Intervention: HIV-positive patients with no preoperative contamination
Number of subjects: 41
Study: 10334141

Group type: EXPERIMENTAL
Intervention: Relaxation feedback during rebreathing 7% CO2/93% O2
Number of subjects: 30

Group type: COMPARATOR
Intervention: No feedback session
Number of subjects: 30
Study: 8922875

Group type: EXPERIMENTAL
Intervention: Reformulated 2-rod Norplant implant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Original 2-rod Norplant implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both implants
Number of subjects: 0
Study: 1417482

Group type: EXPERIMENTAL
Intervention: Supranormal values of cardiac index (> or = 4.52 L/min per square meter), oxygen delivery (> or = 670 mL/min per square meter), and oxygen consumption (> or = 166 mL/min per square meter)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal values for all hemodynamic measurements (control group)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Supranormal values
Number of subjects: 67
Study: 4084899

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose 3.78 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Desipramine (mean daily dose 208 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Alprazolam
Number of subjects: 54

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Alprazolam and Desipramine
Number of subjects: 54
Study: 28906348

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study: 28954546

Group type: EXPERIMENTAL
Intervention: Peer facilitators
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Expert facilitators
Number of subjects: 225
Study: 26505413

Group type: EXPERIMENTAL
Intervention: Randomly selected gene groups (1000, 100, 50, 30, 10, 5, and 3 genes selected 1000 times)
Number of subjects: 53
Study: 24239841

Group type: EXPERIMENTAL
Intervention: Ablation management (AM) with phased RF ablation
Number of subjects: 210

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ablation management (AM)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Ablation management (AM) and Medical management (MM)
Number of subjects: 210
Study: 22612526

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 631
Study: 20014607

Group type: EXPERIMENTAL
Intervention: ProAct (PA) laryngeal mask airway
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Meditech Systems Limited (MSL) laryngeal mask airway
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classic Laryngeal Mask Airway (cLMA)
Number of subjects: 120
Study: 17484740

Group type: EXPERIMENTAL
Intervention: Exercise intervention guided by the Levine Conservation Model; details on dosage and duration not specified.
Number of subjects: 0
Study: 15192321

Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 11336588

Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) co-administered with nucleoside reverse transcriptase inhibitors (nRTIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) co-administered with ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) co-administered with nelfinavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) with ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir and saquinavir
Number of subjects: 0
Study: 8365284

Group type: EXPERIMENTAL
Intervention: 600 mg aerosolized pentamidine once monthly
Number of subjects: 151

Group type: COMPARATOR
Intervention: 300 mg aerosolized pentamidine twice monthly
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Secondary prophylaxis (one prior episode of PCP)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard dose (300 mg) prophylaxis
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 151
Study: 3534025

Group type: EXPERIMENTAL
Intervention: Topical application of a cream or lotion containing 2% hydroquinone and 0.05% to 0.1% retinoic acid (tretinoin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant use of topical sunscreen preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suspension of oral contraceptives and other agents that promote skin pigmentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monobenzyl ether of hydroquinone
Number of subjects: 0
Study: 30047176

Group type: EXPERIMENTAL
Intervention: Small‐sided ball games (SSG)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Circuit strength training (CST)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 291
Study: 27488098

Group type: EXPERIMENTAL
Intervention: Fresh oranges (1774 μmol of total Citrus flavanones)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pasteurized orange juice (751 μmol of total Citrus flavanones)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments (fresh oranges and orange juice)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fresh oranges
Number of subjects: 12
Study: 25322597

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) based comprehensive treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study: 23106412

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) twice a week
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) once a week
Number of subjects: 141

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 141
Study: 21968659

Group type: EXPERIMENTAL
Intervention: 2.5% THPE-containing cream
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 41
Study: 18334820

Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study: 16566965

Group type: EXPERIMENTAL
Intervention: 10 mL of 2% lignocaine gel with 0.05% chlorhexidine gluconate (group 1, n = 72)
Number of subjects: 141

Group type: COMPARATOR
Intervention: 10 mL of 2% lignocaine and aqueous gel mixture (group 2, n = 69)
Number of subjects: 141
Study: 14738340

Group type: EXPERIMENTAL
Intervention: Right hand tracking on Test 1
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Left hand tracking on Test 2
Number of subjects: 76

Group type: COMPARATOR
Intervention: Left hand tracking on Test 1
Number of subjects: 76

Group type: COMPARATOR
Intervention: Right hand tracking on Test 2
Number of subjects: 76
Study: 10623705

Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine, three weekly intradermal vaccine injections of 10^7 irradiated autologous tumor cells and 10^7 BCG organisms for the first two injections
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine
Number of subjects: 412

Group type: COMPARATOR
Intervention: Observation arm (control)
Number of subjects: 412
Study: 9186094

Group type: EXPERIMENTAL
Intervention: Digital image analysis for measuring corneal haze
Number of subjects: 20
Study: 1326404

Group type: EXPERIMENTAL
Intervention: 8 mg sumatriptan sc
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 3493795

Group type: EXPERIMENTAL
Intervention: Propofol infusion at varying rates (60 to 200 micrograms kg‐1 min‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 72
Study: 29498457

Group type: EXPERIMENTAL
Intervention: Rikkunshito (n=64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (n=61)
Number of subjects: 128
Study: 27593863

Group type: EXPERIMENTAL
Intervention: New nomogram including albumin, base excess, and respiratory rate
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: New nomogram
Number of subjects: 561

Group type: COMPARATOR
Intervention: Conventional scoring system
Number of subjects: 561
Study: 26159999

Group type: EXPERIMENTAL
Intervention: Carriers of cLQTS-associated variants
Number of subjects: 870

Group type: COMPARATOR
Intervention: Non-carriers of cLQTS-associated variants
Number of subjects: 870
Study: 23988639

Group type: EXPERIMENTAL
Intervention: Telmisartan treatment among patients with low eGFR
Number of subjects: 18666

Group type: COMPARATOR
Intervention: Low eGFR
Number of subjects: 18666
Study: 21297492

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus Simvastatin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 19076931

Group type: EXPERIMENTAL
Intervention: anti-IgE treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 16752286

Group type: EXPERIMENTAL
Intervention: Calcium phosphate cement augmentation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (closed reduction and fixation with two cannulated screws)
Number of subjects: 118
Study: 14997032

Group type: EXPERIMENTAL
Intervention: High dose p38 MAPK inhibitor (BIRB 796 BS) 600 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low dose p38 MAPK inhibitor (BIRB 796 BS) 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11766105

Group type: EXPERIMENTAL
Intervention: Mercurochrome
Number of subjects: 72

Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 72

Group type: COMPARATOR
Intervention: Locacorten-vioform
Number of subjects: 72
Study: 9412209

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g once daily parenterally
Number of subjects: 148

Group type: COMPARATOR
Intervention: Cefotaxime 1 g 8 hourly for a minimum of 7 days
Number of subjects: 148
Study: 8314099

Group type: EXPERIMENTAL
Intervention: Treatment group (individual and family counseling, support group participation, and ad hoc consultation)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (only routine support)
Number of subjects: 2
Study: 2945652

Group type: EXPERIMENTAL
Intervention: Colon Perfusion Fluid ¢ñ
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 19
Study: 30130147

Group type: EXPERIMENTAL
Intervention: L-Dex measurement using the L-Dex U400 device
Number of subjects: 280

Group type: COMPARATOR
Intervention: Normative values for L-Dex
Number of subjects: 280
Study: 26720598

Group type: EXPERIMENTAL
Intervention: 6-week supervised pelvic floor muscle exercise (PFME) program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (PFME and stop test training)
Number of subjects: 70
Study: 25261967

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 6729
Study: 21863338

Group type: EXPERIMENTAL
Intervention: VivaGel(®)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo gels
Number of subjects: 61

Group type: COMPARATOR
Intervention: All gels (including VivaGel(®) and placebo)
Number of subjects: 61
Study: 20199360

Group type: EXPERIMENTAL
Intervention: 24-hour 10-mg controlled-release vaginal dinoprostone pessary
Number of subjects: 133

Group type: COMPARATOR
Intervention: Repeat doses of 2 mg vaginal dinoprostone gel
Number of subjects: 133
Study: 18544523

Group type: EXPERIMENTAL
Intervention: Ametop
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 20
Study: 15660542

Group type: EXPERIMENTAL
Intervention: Saline group - catheters flushed with 3 mL of normal saline 0.9% after each catheter use
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Heparin group - catheters flushed with 3 mL of 100-U/mL heparin in normal saline 0.9% after each catheter use
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group - catheters not flushed following drug administration
Number of subjects: 300
Study: 12647328

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Time-Limited Dynamic Psychotherapy (TLDP)
Number of subjects: 136
Study: 10483544

Group type: EXPERIMENTAL
Intervention: Gel containing 0.5 mg of dinoprostone placed intracervically every four hours
Number of subjects: 69

Group type: COMPARATOR
Intervention: Polymer insert containing 10 mg of dinoprostone intravaginally
Number of subjects: 69
Study: 8673544

Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen (inactivated, gp120‐depleted HIV‐1 virus in incomplete Freund's adjuvant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen
Number of subjects: 0
Study: 1833167

Group type: EXPERIMENTAL
Intervention: OKT3 prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine prophylaxis
Number of subjects: 0
Study: 6349926

Group type: EXPERIMENTAL
Intervention: Daily vitamin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31928445

Group type: EXPERIMENTAL
Intervention: Thirty days exposure to time-estimation tasks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control conditions (without exposure to time estimation tasks)
Number of subjects: 22